Özet:

Objective: S100B is a calcium-binding protein that is secreted from astrocytes and other glial cells in the central nervous system and may affect the growth and/or differentiation of neurons and astrocytes. The neuropathological studies in cell cultures of Toxoplasma gondii and postmortem studies in patients with schizophrenia revealed many glial abnormalities, particularly in astrocytes. This study aimed to evaluate S100B protein levels in patients with schizophrenia having seropositive and seronegative toxoplasma. Methods: This study included 40 patients with schizophrenia and 39 healthy control groups, with 20 toxoplasma seropositive in each group. The patients’ psychopathology were evaluated with the positive and negative syndrome scale (PANSS). S100B level and T. gondii immunoglobulin G (IgG) were analyzed by electrochemiluminescence immunoassay and the enzyme-linked immune-sorbent assay method, respectively. Results: No significant difference was found in S100B values between the patients with schizophrenia and healthy controls (p=0.94). No statistically significant correlations were found between S100B and both PANSS subscale scores and disease duration. S100B median values between toxoplasma IgG-positive and negative groups have no statistically significant difference in both healthy controls (p=0.38) and patients with schizophrenia (p=0.93). Conclusion: This study found no association between S100B protein levels and both schizophrenia and latent toxoplasma. Some studies report a role for S100B in schizophrenia; however, uncertainties still exist and are in some ways contradictory.

Anahtar Kelimeler: